Amylyx Pharmaceuticals Inc (AMLX) Stock Price, Quote & News

Company Profile

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of so...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 682 0917

Website: amylyx.com

Address:

55 Cambridge Parkway, Suite 6W, Cambridge, United States

vu_jade Jun. 12 at 6:29 PM

$AMLX what’s the consensus here ? Q3 news?

0 · Reply

LoveRetailFroth Jun. 12 at 2:03 PM

$AMLX Good Morning bio💎 $40🚀

0 · Reply

SilentBull69 Jun. 11 at 10:47 PM

$AMLX Getting closer to the end of the month Time to start moving up …unless these algorithms wanna keep us down for a bit longer …just because they can 🤔

0 · Reply

LoveRetailFroth Jun. 11 at 7:45 PM

$AMLX Thi weekend is the ENDO conference🚀 $25 By December $40

0 · Reply

MarketBeat Jun. 10 at 10:13 PM

https://marketbeat.com/a/8706095/ $AMLX Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape

0 · Reply

SilentBull69 Jun. 10 at 4:45 PM

$AMLX Algorithms hard at work keeping this down… it’s crazy how easy it is for them Don’t believe me …look at all the hundred trade blocks on both the ask and the bid sides And less than 400,000 volume Those are computer generated blocks, not human

1 · Reply

LoveRetailFroth Jun. 10 at 2:03 PM

$AMLX 💎 was is on sale😂 $40

0 · Reply

LoveRetailFroth Jun. 10 at 1:15 PM

$AMLX Good Morning my Bio gem💎s☕️ $RXRX $TEM $SANA

0 · Reply

LoveRetailFroth Jun. 9 at 7:05 PM

$AMLX 💎

0 · Reply

11thestate Jun. 9 at 4:02 PM

$AMLX settlement update: claims are now open. Amylyx has agreed to a $6.5M settlement over allegations that investors were misled about demand for Relyvrio, its ALS treatment. The stock fell nearly 32% after the company disclosed slowing patient growth. Deadline to file: Aug. 31, 2026 https://11th.com/cases/amylyx-pharmaceutical-investor-settlement

0 · Reply

Amylyx Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 9:00 AM EDT - 4 days ago

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

Jun 4, 2026, 9:00 AM EDT - 8 days ago

Amylyx Pharmaceuticals Transcript: AGM 2026

2026-05-15T17:48:26.000Z - 4 weeks ago

Amylyx announces publication of Phase 2 open-label HELIOS trial data

May 15, 2026, 12:11 PM EDT - 4 weeks ago

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

May 13, 2026, 4:40 PM EDT - 4 weeks ago

Amylyx Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

2026-05-07T16:21:43.000Z - 5 weeks ago

Amylyx sees cash runway into 2028

May 7, 2026, 8:00 AM EDT - 5 weeks ago

Amylyx Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 5 weeks ago

Amylyx Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 5 weeks ago

Amylyx Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 5 weeks ago

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

May 6, 2026, 9:00 AM EDT - 5 weeks ago

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

2026-05-05T11:36:12.000Z - 5 weeks ago

Amylyx announces launch of U.S. EAP for adults with PBH

May 5, 2026, 7:00 AM EDT - 5 weeks ago

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Apr 30, 2026, 9:00 AM EDT - 6 weeks ago

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

2026-04-28T10:58:40.000Z - 6 weeks ago

Amylyx price target raised to $21 from $19 at Mizuho

Apr 23, 2026, 8:00 AM EDT - 7 weeks ago

Amylyx Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 7 weeks ago

Amylyx Pharmaceuticals Proxy statement: Proxy filing

Apr 15, 2026, 8:45 AM EDT - 2 months ago

Amylyx Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:54 PM EDT - 2 months ago

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Apr 8, 2026, 9:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

2026-03-24T11:05:57.000Z - 2 months ago

Amylyx completes enrollment in Phase 3 Lucidity trial of avexitide

Mar 24, 2026, 7:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

2026-03-19T10:50:43.000Z - 3 months ago

Amylyx price target raised to $30 from $25 at Guggenheim

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Amylyx Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-04T14:38:10.000Z - 3 months ago

Amylyx price target raised to $34 from $28 at H.C. Wainwright

Mar 3, 2026, 11:10 AM EST - 3 months ago

Amylyx Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-03T13:12:32.000Z - 3 months ago

Amylyx files automatic mixed securities shelf

Mar 3, 2026, 8:00 AM EST - 3 months ago

Amylyx Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 3, 2026, 8:00 AM EST - 3 months ago

Amylyx Pharmaceuticals Annual report: Q4 2025

Mar 3, 2026, 8:00 AM EST - 3 months ago

Amylyx Pharmaceuticals Earnings release: Q4 2025

2026-03-03T12:37:16.000Z - 3 months ago

Amylyx reports Q4 EPS (30c), consensus (34c)

Mar 3, 2026, 7:00 AM EST - 3 months ago

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

2026-03-02T21:11:21.000Z - 3 months ago

Amylyx initiated with a Buy at Stifel

Mar 2, 2026, 6:00 AM EST - 3 months ago

Amylyx Pharmaceuticals Slides: Corporate presentation

Feb 26, 2026, 9:00 AM EST - 3 months ago

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Feb 24, 2026, 9:00 AM EST - 3 months ago

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

2026-02-20T12:26:13.000Z - 4 months ago

Amylyx price target raised to $19 from $15 at BofA

2026-02-19T12:36:40.000Z - 4 months ago

Amylyx price target raised to $19 from $18 at Mizuho

2026-02-19T12:29:43.000Z - 4 months ago

Amylyx price target raised to $19 from $18 at Mizuho

2026-02-10T11:19:36.000Z - 4 months ago

Amylyx price target raised to $28 from $20 at H.C. Wainwright

Jan 29, 2026, 5:05 PM EST - 4 months ago

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

2026-01-08T12:16:47.000Z - 5 months ago

Amylyx selects AMX0318 as development candidate for PBH

Jan 8, 2026, 7:00 AM EST - 5 months ago

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

2025-12-19T14:11:21.000Z - 6 months ago

Amylyx price target lowered to $15 from $16 at BofA

Dec 5, 2025, 9:00 AM EST - 6 months ago

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

Dec 3, 2025, 4:00 PM EST - 6 months ago

Amylyx Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 8:20 AM EST - 6 months ago

Amylyx Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 10, 2025, 4:30 PM EST - 7 months ago

Amylyx Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-10T12:31:55.000Z - 7 months ago

Amylyx price target raised to $18 from $16 at Mizuho

2025-11-07T13:05:38.000Z - 7 months ago

Amylyx price target raised to $20 from $16 at H.C. Wainwright

Nov 6, 2025, 8:00 AM EST - 7 months ago

Amylyx Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Amylyx Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Amylyx Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 9:00 AM EST - 7 months ago

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

Oct 30, 2025, 9:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 27, 2025, 12:20 PM EDT - 8 months ago

Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Sep 12, 2025, 7:30 AM EDT - 9 months ago

Amylyx Pharmaceuticals Slides: Corporate Presentation

Sep 10, 2025, 10:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 12:06 AM EDT - 9 months ago

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

Sep 9, 2025, 4:01 PM EDT - 9 months ago

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Sep 9, 2025, 3:10 PM EDT - 9 months ago

Amylyx Pharmaceuticals Transcript: Baird Global Healthcare Conference 2025

Sep 8, 2025, 4:50 PM EDT - 9 months ago

Amylyx Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 1:00 PM EDT - 10 months ago

Amylyx Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Aug 27, 2025, 7:28 AM EDT - 10 months ago

Amylyx to stop development of rare brain disorder drug after trial failure

Aug 27, 2025, 7:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 9:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 13, 2025, 9:00 PM EDT - 11 months ago

Amylyx Pharmaceuticals Transcript: Status Update

Jul 13, 2025, 9:00 PM EDT - 11 months ago

Amylyx Pharmaceuticals Press release: Status Update

Jul 13, 2025, 9:00 PM EDT - 11 months ago

Amylyx Pharmaceuticals Slides: Status Update

Jul 13, 2025, 5:00 PM EDT - 11 months ago

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

Jul 8, 2025, 7:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025

Jun 10, 2025, 3:20 PM EDT - 1 year ago

Amylyx Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 1:25 PM EDT - 1 year ago

Amylyx Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Jun 2, 2025, 4:00 PM EDT - 1 year ago

Amylyx Pharmaceuticals Slides: Investor Presentation

May 21, 2025, 7:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 20, 2025, 5:00 PM EDT - 1 year ago

Amylyx Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 13, 2025, 4:55 PM EDT - 1 year ago

Amylyx Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

May 12, 2025, 7:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

May 8, 2025, 8:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

May 7, 2025, 8:00 AM EDT - 1 year ago

Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

vu_jade Jun. 12 at 6:29 PM

$AMLX what’s the consensus here ? Q3 news?

0 · Reply

LoveRetailFroth Jun. 12 at 2:03 PM

$AMLX Good Morning bio💎 $40🚀

0 · Reply

SilentBull69 Jun. 11 at 10:47 PM

$AMLX Getting closer to the end of the month Time to start moving up …unless these algorithms wanna keep us down for a bit longer …just because they can 🤔

0 · Reply

LoveRetailFroth Jun. 11 at 7:45 PM

$AMLX Thi weekend is the ENDO conference🚀 $25 By December $40

0 · Reply

MarketBeat Jun. 10 at 10:13 PM

https://marketbeat.com/a/8706095/ $AMLX Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape

0 · Reply

SilentBull69 Jun. 10 at 4:45 PM

1 · Reply

LoveRetailFroth Jun. 10 at 2:03 PM

$AMLX 💎 was is on sale😂 $40

0 · Reply

LoveRetailFroth Jun. 10 at 1:15 PM

$AMLX Good Morning my Bio gem💎s☕️ $RXRX $TEM $SANA

0 · Reply

LoveRetailFroth Jun. 9 at 7:05 PM

$AMLX 💎

0 · Reply

11thestate Jun. 9 at 4:02 PM

0 · Reply

LoveRetailFroth Jun. 9 at 1:01 PM

$AMLX Good Morning ☕️😂 lol $35- $40

0 · Reply

LoveRetailFroth Jun. 8 at 3:28 PM

$AMLX Good Morning ☕️ $34-$40 . LT $70-$100

0 · Reply

ajmore Jun. 8 at 1:43 PM

$AMLX Wainwright reinterates Buy and target 34!

1 · Reply

ajmore Jun. 8 at 1:24 PM

$AMLX announces poster presentation at ENDO 2026 13-16 June. Avexitide in focus.

1 · Reply

SilentBull69 Jun. 5 at 9:58 PM

$AMLX Where is the circuit breaker for dropping past 10% in one low volume trading day Does this corruption ever end ..??🤔

1 · Reply

SilentBull69 Jun. 5 at 4:34 PM

$AMLX And the games continue with these algorithms ….. Every one of those “100 block” trades .. are all created by the algorithms …on both the bid and the ask side they have completely nullified retail movement And again all of this …with under 400,000 share volume movement

1 · Reply

Quantumup Jun. 5 at 11:56 AM

Roth • MKM🏁 $COYA and said: We initiate coverage of COYA with a Buy rating and 12-month PT of $12. $AMLX BIIB LLY NRSN LONA CLNN $IONS Here's what Roth • MKM went on to say: https://x.com/Quantumup1/status/2062865648150020118?s=20

0 · Reply

focafoca99 Jun. 4 at 8:26 PM

$AMLX voted its shareholders approved the election of two directors, ratified Deloitte & Touche as its auditor and gave advisory approval to

0 · Reply

LoveRetailFroth Jun. 4 at 6:39 PM

$AMLX 🚀 $40, $50, $70…. $100

0 · Reply

LoveRetailFroth Jun. 4 at 3:14 PM

$RXRX These will be violent upsides 😂🚀☕️ $AMLX $TEM $SANA

0 · Reply

LoveRetailFroth Jun. 4 at 1:25 PM

$AMLX Good Morning ☕️ Bio 💎 s to $40 . $SANA

0 · Reply

SilentBull69 Jun. 3 at 6:08 PM

$AMLX Upcoming catalyst, 😎 these algorithms can’t keep it down forever👍✌️

0 · Reply

Market Cap	1.55B
Revenue (ttm)	0.00
Net Income (ttm)	-144.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,693,700
Avg Vol	1,198,656
Day's Range	N/A - N/A
Shares Out	111.19M
Stochastic %K	88%
Beta	-0.16
Analysts	Strong Sell
Price Target	$23.40